**Core Concept**
Hepatorenal syndrome (HRS) is a type of progressive kidney dysfunction seen in patients with advanced liver disease, particularly cirrhosis. The pathophysiology involves splanchnic vasodilation, decreased effective circulating volume, and activation of vasoconstrictor systems, leading to renal vasoconstriction and impaired renal function.

**Why the Correct Answer is Right**
The treatment of HRS is primarily focused on addressing the underlying liver disease and improving circulatory function. Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that creates a shunt between the hepatic vein and the portal vein, reducing portal pressure and improving renal perfusion. This is the most effective treatment for HRS, especially in patients with advanced liver disease. TIPS can improve renal function and increase survival in patients with HRS.

**Why Each Wrong Option is Incorrect**
**Option A:** Tissue plasminogen activator (tPA) is used to treat thrombotic disorders, not HRS. It is not effective in addressing the underlying pathophysiology of HRS.
**Option B:** Octreotide is a somatostatin analogue used to treat bleeding esophageal varices and portal hypertensive gastropathy, but it is not the best treatment for HRS.
**Option C:** Midodrine is a vasopressor used to treat hypotension, but it can worsen renal vasoconstriction and is not effective in treating HRS.

**Clinical Pearl / High-Yield Fact**
TIPS is a life-saving procedure for patients with HRS, but it is associated with a high risk of complications, including hepatic encephalopathy and shunt dysfunction.

**Correct Answer:** C. Midodrine